- Dupilumab and tezepelumab showed identical asthma exacerbation rates at 22% each.
- Dupilumab users had slightly higher corticosteroid use and more adverse events.
- Both biologics reduced eosinophil counts, with no significant difference.
- Study analyzed 1,898 adults from 69 U.S. health systems between 2015 and 2023.
- Lead author Adeel Nasrullah, MD, said results help personalize asthma therapy.
Asthma Exacerbations Equal With Two Biologics
Conexiant
October 24, 2025
